ALPN Alpine Immune Sciences
Nivalis Therapeutics Inc a pharmaceutical company, focuses on the discovery and development of product candidates for patients with cystic fibrosis. Geographically operation of the group is functioned through United States.
$8.30 +0.02 (0.24%)
As of 02/02/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: USA
IPO date: 06/17/2015
Outstanding shares: 30,400,679
Average volume: 86,393
Market cap: $251,717,622
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol: BYX38M1
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%